Zobrazeno 1 - 10
of 710
pro vyhledávání: '"Kris V. Kowdley"'
Publikováno v:
JGH Open, Vol 7, Iss 12, Pp 848-854 (2023)
Abstract Background and Aim Hepatorenal syndrome (HRS) is a life‐threatening complication of advanced liver disease. This study aimed to examine the impact of hospital teaching/transplant status and availability of liver transplantation on survival
Externí odkaz:
https://doaj.org/article/2e554b0048dd452cae18ec36efd70b4b
Autor:
Mary E. Rinella, Jeffrey V. Lazarus, Vlad Ratziu, Sven M. Francque, Arun J. Sanyal, Fasiha Kanwal, Diana Romero, Manal F. Abdelmalek, Quentin M. Anstee, Juan Pablo Arab, Marco Arrese, Ramon Bataller, Ulrich Beuers, Jerome Boursier, Elisabetta Bugianesi, Christopher D. Byrne, Graciela E. Castro Narro, Abhijit Chowdhury, Helena Cortez-Pinto, Donna R. Cryer, Kenneth Cusi, Mohamed El-Kassas, Samuel Klein, Wayne Eskridge, Jiangao Fan, Samer Gawrieh, Cynthia D. Guy, Stephen A. Harrison, Seung Up Kim, Bart G. Koot, Marko Korenjak, Kris V. Kowdley, Florence Lacaille, Rohit Loomba, Robert Mitchell-Thain, Timothy R. Morgan, Elisabeth E. Powell, Michael Roden, Manuel Romero-Gómez, Marcelo Silva, Shivaram Prasad Singh, Silvia C. Sookoian, C. Wendy Spearman, Dina Tiniakos, Luca Valenti, Miriam B. Vos, Vincent Wai-Sun Wong, Stavra Xanthakos, Yusuf Yilmaz, Zobair Younossi, Ansley Hobbs, Marcela Villota-Rivas, Philip N. Newsome
Publikováno v:
Annals of Hepatology, Vol 29, Iss 1, Pp 101133- (2024)
The principal limitations of the terms NAFLD and NASH are the reliance on exclusionary confounder terms and the use of potentially stigmatising language. This study set out to determine if content experts and patient advocates were in favor of a chan
Externí odkaz:
https://doaj.org/article/f02c612b79da4aaa8837228f72393227
Autor:
Michael Trauner, Chuhan Chung, Kate Sterling, Xiangyu Liu, Xiaomin Lu, Jun Xu, Clare Tempany-Afdhal, Zachary D. Goodman, Martti Färkkilä, Atsushi Tanaka, Palak Trivedi, Kris V. Kowdley, Christopher L. Bowlus, Cynthia Levy, Robert P. Myers
Publikováno v:
BMC Gastroenterology, Vol 23, Iss 1, Pp 1-11 (2023)
Abstract Background Primary sclerosing cholangitis (PSC) is a chronic progressive liver disease leading to biliary fibrosis and cirrhosis. Cilofexor is a nonsteroidal farnesoid X receptor agonist that demonstrated significant improvements in liver bi
Externí odkaz:
https://doaj.org/article/f6de658e3d0a4a3c807ec2a098703885
Autor:
Jessica T. Hochberg, Aalam Sohal, Priya Handa, Bryan D. Maliken, Take-Kyun Kim, Kai Wang, Eric Gochanour, Yu Li, J. Bart Rose, James E. Nelson, Keith D. Lindor, Nicholas F. LaRusso, Kris V. Kowdley
Publikováno v:
JHEP Reports, Vol 5, Iss 6, Pp 100729- (2023)
Background & Aims: Primary sclerosing cholangitis (PSC) is a chronic, progressive cholestatic liver disease that can lead to end-stage liver disease and cholangiocarcinoma. High-dose ursodeoxycholic acid (hd-UDCA, 28–30 mg/kg/day) was evaluated in
Externí odkaz:
https://doaj.org/article/5f55f7c82ccc4e648d616781d4396537
Publikováno v:
Hepatology Communications, Vol 6, Iss 8, Pp 1842-1854 (2022)
Abstract Iron overload disorders represent a variety of conditions that lead to increased total body iron stores and resultant end‐organ damage. An elevated ferritin and transferrin‐iron saturation can be commonly encountered in the evaluation of
Externí odkaz:
https://doaj.org/article/2276650b0e874dbf974fcd02e4dc5f05
Autor:
Christoph Schramm, Heiner Wedemeyer, Andrew Mason, Gideon M. Hirschfield, Cynthia Levy, Kris V. Kowdley, Piotr Milkiewicz, Ewa Janczewska, Elena Sergeevna Malova, Johanne Sanni, Phillip Koo, Jin Chen, Subhajit Choudhury, Lloyd B. Klickstein, Michael K. Badman, David Jones
Publikováno v:
JHEP Reports, Vol 4, Iss 11, Pp 100544- (2022)
Background & Aims: The safety, tolerability, and efficacy of the non-bile acid farnesoid X receptor agonist tropifexor were evaluated in a phase II, double-blind, placebo-controlled study as potential second-line therapy for patients with primary bil
Externí odkaz:
https://doaj.org/article/3923e32517ec458db31731c6b79c2204
Autor:
Zobair M. Younossi, Maria Stepanova, Mazen Noureddin, Kris V. Kowdley, Simone I. Strasser, Anita Kohli, Peter Ruane, Mitchell L. Shiffman, Aasim Sheikh, Nadege Gunn, Stephen H. Caldwell, Ryan S. Huss, Robert P. Myers, Vincent Wai‐Sun Wong, Naim Alkhouri, Zachary Goodman, Rohit Loomba
Publikováno v:
Hepatology Communications, Vol 5, Iss 7, Pp 1201-1211 (2021)
Patient‐reported outcomes (PROs) are important endpoints for clinical trials. The impact of investigational drugs on PROs of patients with advanced nonalcoholic steatohepatitis (NASH) was investigated. Patients with NASH with bridging fibrosis or c
Externí odkaz:
https://doaj.org/article/10bc3bc5921042808f8b0f85eb39a5a0
Publikováno v:
Hepatology Communications, Vol 5, Iss 5, Pp 723-735 (2021)
Hepcidin, a peptide hormone produced by hepatocytes, is the central regulator of systemic iron homeostasis through its interaction with ferroportin, the major cellular iron export protein. Hepcidin binding to ferroportin results in reduced iron expor
Externí odkaz:
https://doaj.org/article/0b7543b6aad44b4ba57c6aad03a69664
Autor:
Samer Gawrieh, Laura A. Wilson, Katherine P. Yates, Oscar W. Cummings, Eduardo Vilar‐Gomez, Veeral Ajmera, Kris V. Kowdley, William M. Rosenberg, James Tonascia, Naga Chalasani
Publikováno v:
Hepatology Communications, Vol 5, Iss 5, Pp 786-797 (2021)
Enhanced liver fibrosis score (ELF) and one of its components, amino‐terminal propeptide of type III procollagen (PIIINP) are promising noninvasive biomarkers of liver histology in patients with nonalcoholic steatohepatitis (NASH). We evaluated the
Externí odkaz:
https://doaj.org/article/d940068a3600448cba93562e817b652c
Autor:
John Scott, Meaghan Fagalde, Atar Baer, Sara Glick, Elizabeth Barash, Hilary Armstrong, Kris V. Kowdley, Matthew R. Golden, Alexander J. Millman, Noele P. Nelson, Lauren Canary, Matthew Messerschmidt, Pallavi Patel, Michael Ninburg, Jeff Duchin
Publikováno v:
Hepatology Communications, Vol 5, Iss 3, Pp 387-399 (2021)
Hepatitis C virus (HCV) infection is common in the United States and leads to significant morbidity, mortality, and economic costs. Simplified screening recommendations and highly effective direct‐acting antivirals for HCV present an opportunity to
Externí odkaz:
https://doaj.org/article/aa74e30f1270433f87451407cd4ebf87